Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 5, 2021The Anatolian Journal of CardiologyOpen Access

Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Doxorubicin is a known cardiotoxic agent, while sacubitril/valsartan is effective in heart failure, motivating evaluation of sacubitril/valsartan on doxorubicin-induced cardiotoxicity.

Does sacubitril/valsartan prevent doxorubicin-induced cardiotoxicity in a pretreatment mice model?

Population

24 mice

Comparison

Control vs DOX vs Sac/Val vs Sac/Val+DOX

Design

Preclinical animal study

Follow-up

9 days

Authors

FDFerhat DindaşUsak UniversityHGHüseyin GüngörSivas Cumhuriyet ÜniversitesiMEMehmet Eki̇ci̇Sivas Cumhuriyet Üniversitesi

Discussion

Loading...

Member takes

Overview

Hypothesis-generating for sacubitril/valsartan in doxorubicin cardiotoxicity; requires clinical trials before any practice consideration.

Structured PICO

Does sacubitril/valsartan prevent doxorubicin-induced cardiotoxicity in a pretreatment mice model?

P
Population
24 Balb-c mice (4-6 weeks old, 18-20 g)
I
Intervention
Sacubitril/valsartan 80 mg/kg perioral daily for 9 days, with doxorubicin 20 mg/kg intraperitoneal administered on the 5th day
C
Comparator
Doxorubicin alone (perioral saline for 9 days + doxorubicin 20 mg/kg intraperitoneal on 5th day), sacubitril/valsartan alone, and control (saline only)
O
Outcome
Electrocardiography parameters (QRS, ST, QT, PP segment, QT/PQ index), oxidative stress markers (TAS, TOS), inflammatory cytokines (TNF-α, IL-1β, IL-6), NT-proBNP concentrations, and Caspase 3 activity at 9 dayssurrogate

Pretreatment with sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a mouse model by reducing oxidative stress, inflammation, and apoptosis.

Cite This Study

Dindaş et al. (2021) studied this question.

synapsesocial.com/papers/6a835e5ce3d18239dbb48b52https://doi.org/10.5152/anatoljcardiol.2021.356
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients With Atrial Fibrillation and in Pressure Overload-Induced Mice2019 · 48 citations
  2. 2Troponin-T and Brain Natriuretic Peptide as Predictors for Adriamycin-Induced Cardiomyopathy in Rats2004 · 79 citations
  3. 3Chronic Treatment with Atrial Natriuretic Peptide in Spontaneously Hypertensive Rats: Beneficial Renal Effects and Sex Differences2015 · 18 citations
  4. 4Prevention of Dystrophin-Deficient Cardiomyopathy in Twenty-One-Month-Old Carrier Mice by Mosaic Dystrophin Expression or Complementary Dystrophin/Utrophin Expression2007 · 122 citations
  5. 5Effects of TNF-alpha on [Ca2+]i and contractility in isolated adult rabbit ventricular myocytes1996 · 132 citations